Abstract:transforming the tumor microenvironment from an anti-tumorigenic to a pro-tumorigenic state (Sun & Yu, 2015). Recent findings establish the crucial significance of tumor microenvironment and cancer stem cells in the development of drug resistance, which is the primary cause of cancer recurrence and its inability to be cured. The presence of genetic variations across individuals and tumors, together with the ability of cancer to evade conventional treatments, further complicates the management of medication resistance.Despite rapid development in the design of novel chemotherapy drugs, there is still a lack of effective agents targeting the advanced stages of cancer, namely invasion and metastasis.Through this research topic, we intended to illuminate promising lines of inquiry, namely focusing on new approaches recently discovered in the field, including fundamental genetics, genomic engineering, omics techniques, artificial intelligence, and machine learning. Our goal was to uncover the molecular basis of drug resistance in various cancers, so guiding clinicians in designing and developing therapeutic strategies to improve therapeutic drug sensitivity and overcome resistance. Research presented in this topic showcase novel approaches and openly address the limitations of existing therapeutic remedies. Research papers collected for this topic elucidate the key mechanisms underlying cancer drug resistance and explore potential therapeutic strategies to overcome this obstacle.Several mechanisms have been identified that confer drug resistance in cancer cells. These include increased drug efflux, alterations in drug targets, activation of alternative signaling pathways, and enhanced DNA repair mechanisms (Fernández-Lázaro, 2018). Cancer stem cells have emerged as key contributors to the development of drug resistance and tumor relapse. (Bukowski et al., 2020) (Sun & Yu, 2015).The integration of multi-omics technology, computational methodologies, and the creation of tailored medicines presents novel approaches to address the issue of drug resistance. In conclusion, the challenge of multidrug resistance in cancer remains a significant obstacle in achieving effective and durable cancer therapy. Understanding the complex and heterogeneous mechanisms underlying drug resistance is crucial for developing novel therapeutic strategies.Advancements in cancer immunotherapy, the creation of immune checkpoint inhibitors or targeted small molecules, and the repurposing of non-oncology medications have expanded the scope of ongoing pharmaceutical research. The advancement of nanotechnology-based drug delivery systems has provided promising avenues to overcome these resistance mechanisms and improve patient outcomes. In this context, the application of emerging technologies, such as CRISPR-Cas9-based gene editing, may prove valuable in combating multidrug resistance genes and enhancing the efficacy of cancer treatments.

Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

A protracted war against cancer drug resistance

Unveiling the mechanisms and challenges of cancer drug resistance

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition

A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy

Editorial: Revisiting the challenges and opportunities in cancer drug resistance

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance

PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Targeting PI3K in cancer: mechanisms and advances in clinical trials

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Targeting PI3K/Akt signal transduction for cancer therapy

Updates on altered signaling pathways in tumor drug resistance

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance